Literature DB >> 25678185

Serum insulin-like growth factor 1 and late-life depression: a population-based study.

N C van Varsseveld1, C C van Bunderen2, E Sohl3, H C Comijs4, B W J H Penninx4, P Lips2, M L Drent2.   

Abstract

OBJECTIVE: Serum insulin-like growth factor 1 (IGF-1) concentration decreases, while the prevalence of depressive symptoms increases with advancing age. Although basic research indicates a link between low IGF-1 concentration and depression, this has scarcely been investigated in humans. This study investigates whether lower IGF-1 concentrations are associated with prevalent and incident late-life depression over a 3-year period.
METHODS: The study included 1188 participants, aged ≥ 65 years, from the Longitudinal Aging Study Amsterdam (LASA), an ongoing, population-based cohort study. Depression was assessed at baseline and after three years using the Center for Epidemiological Studies-Depression Scale (CES-D) and the Diagnostic Interview Schedule (DIS), and categorized into minor depression and major depression (MDD). Serum IGF-1 concentration was determined at baseline. Associations were adjusted for relevant confounders.
RESULTS: Serum IGF-1 concentrations were within the normal range (mean 13.9 nmol/l, standard deviation 5.3 nmol/l). At baseline, in men, as compared to high concentrations, mid concentrations decreased the probability of prevalent minor depression (odds ratio [OR] = 0.35, 95% confidence interval [CI] = 0.15-0.82). In women, as compared to high concentrations, low concentrations tended to increase the probability of prevalent MDD (OR = 2.66, 95% CI = 0.89-7.89). At three-year follow-up, in men, no significant prospective associations were detected. In women, as compared to high concentrations, mid concentrations decreased the probability of incident minor depression (OR = 0.43, 95% CI = 0.19-0.95).
CONCLUSIONS: Several associations, which differed across the genders, were observed between IGF-1 and depression. Cross-sectional findings were not supported by longitudinal findings, which suggest that IGF-1 may not play an important predictive role in the development of depression in older persons over time. However, a more acute role of IGF-1 in current depression, as indicated by the cross-sectional results, may be possible. Further studies are needed to elucidate the complex relation between IGF-1 and late-life depression.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Depression; Depressive symptoms; Elderly; Insulin-like growth factor 1

Mesh:

Substances:

Year:  2015        PMID: 25678185     DOI: 10.1016/j.psyneuen.2015.01.014

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  13 in total

Review 1.  Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies.

Authors:  Ajaykumar N Sharma; Bruno Fernando Borges da Costa e Silva; Jair C Soares; André F Carvalho; Joao Quevedo
Journal:  J Affect Disord       Date:  2016-03-02       Impact factor: 4.839

2.  The Diagnostic Value of the Combination of Serum Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor-1 for Major Depressive Disorder Diagnosis and Treatment Efficacy.

Authors:  Alexandra S Troyan; Oleg A Levada
Journal:  Front Psychiatry       Date:  2020-08-13       Impact factor: 4.157

3.  Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors.

Authors:  Felix P Bernhard; Sebastian Heinzel; Gerhard Binder; Karin Weber; Anja Apel; Benjamin Roeben; Christian Deuschle; Mirjam Maechtel; Tanja Heger; Susanne Nussbaum; Thomas Gasser; Walter Maetzler; Daniela Berg
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

Review 4.  Depression and frailty in later life: a systematic review.

Authors:  Leslie Vaughan; Akeesha L Corbin; Joseph S Goveas
Journal:  Clin Interv Aging       Date:  2015-12-15       Impact factor: 4.458

5.  Insulin-like growth factor 1 and risk of depression in older people: the English Longitudinal Study of Ageing.

Authors:  S Chigogora; P Zaninotto; M Kivimaki; A Steptoe; G D Batty
Journal:  Transl Psychiatry       Date:  2016-09-20       Impact factor: 6.222

6.  Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha (TGFα) as a potential biomarker of consumption and dual diagnosis.

Authors:  Rosa Maza-Quiroga; Nuria García-Marchena; Pablo Romero-Sanchiz; Pedro Araos; Vicente Barrios; María Pedraz; Antonia Serrano; Raquel Nogueira-Arjona; Juan Jesus Ruiz; Maribel Soria; Rafael Campos; Julie Ann Chowen; Jesus Argente; Marta Torrens; Meritxell López-Gallardo; Eva María Marco; Fernando Rodríguez de Fonseca; Francisco Javier Pavón
Journal:  PeerJ       Date:  2017-10-12       Impact factor: 2.984

Review 7.  Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder.

Authors:  Oleg A Levada; Alexandra S Troyan
Journal:  Ann Gen Psychiatry       Date:  2017-10-26       Impact factor: 3.455

Review 8.  The Role of Insulin-Like Growth Factor 1 in the Progression of Age-Related Hearing Loss.

Authors:  Lourdes Rodríguez-de la Rosa; Luis Lassaletta; Miryam Calvino; Silvia Murillo-Cuesta; Isabel Varela-Nieto
Journal:  Front Aging Neurosci       Date:  2017-12-12       Impact factor: 5.750

9.  The Longitudinal Aging Study Amsterdam: cohort update 2016 and major findings.

Authors:  Emiel O Hoogendijk; Dorly J H Deeg; Jan Poppelaars; Marleen van der Horst; Marjolein I Broese van Groenou; Hannie C Comijs; H Roeline W Pasman; Natasja M van Schoor; Bianca Suanet; Fleur Thomése; Theo G van Tilburg; Marjolein Visser; Martijn Huisman
Journal:  Eur J Epidemiol       Date:  2016-08-20       Impact factor: 8.082

Review 10.  Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA.

Authors:  Kun-Yu Tu; Ming-Kung Wu; Yen-Wen Chen; Pao-Yen Lin; Hung-Yu Wang; Ching-Kuan Wu; Ping-Tao Tseng
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.